These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8200572

  • 1. Diagnostic pitfall; interpretation of CA 19-9 concentrations in the presence of hepatic dysfunction.
    Pearce S, Thornes H, Carr D, Tanner A.
    Gut; 1994 May; 35(5):707-8. PubMed ID: 8200572
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [Abstract] [Full Text] [Related]

  • 3. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    Anticancer Res; 1992 May; 12(6B):2309-14. PubMed ID: 1295478
    [Abstract] [Full Text] [Related]

  • 4. Does serum CAR-3 play a role in pancreatic cancer diagnosis?
    Basso D, Panozzo MP, Fabris C, Meggiato T, Faggian D, Fogar P, Scalon P, Del Favero G, Plebani M, Burlina A.
    Oncology; 1991 May; 48(1):22-5. PubMed ID: 1987495
    [Abstract] [Full Text] [Related]

  • 5. Serum CA 242: the search for a valid marker of pancreatic cancer.
    Ventrucci M, Ubalducci GM, Cipolla A, Panella MA, Ligabue A.
    Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
    [Abstract] [Full Text] [Related]

  • 6. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
    Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E.
    J Cancer Res Clin Oncol; 1994 Mar; 120(8):494-7. PubMed ID: 8207049
    [Abstract] [Full Text] [Related]

  • 7. ERCP combined with tumor markers in differential diagnosis of pancreatic cancer and pseudotumor-like pancreatitis.
    Luo B, Peng F, Hong M, Su S, Fang C, Yang X, Xia G, Li B.
    J BUON; 2019 Mar; 24(4):1568-1573. PubMed ID: 31646810
    [Abstract] [Full Text] [Related]

  • 8. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma.
    Hyöty M, Hyöty H, Aaran RK, Airo I, Nordback I.
    Eur J Surg; 1992 Mar; 158(3):173-9. PubMed ID: 1356458
    [Abstract] [Full Text] [Related]

  • 9. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [Abstract] [Full Text] [Related]

  • 10. [Use of the CA 19-9 tumor marker in the diagnosis of pancreatic carcinoma].
    Kausitz J, Lesný P, Belan V.
    Bratisl Lek Listy; 1993 Apr; 94(4):201-3. PubMed ID: 8353764
    [Abstract] [Full Text] [Related]

  • 11. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
    Plebani M, Basso D, Del Favero G, Ferrara C, Meggiato T, Fogar P, Mangano F, Ricciardi G, Burlina A.
    Oncology; 1993 Apr; 50(6):436-40. PubMed ID: 8233283
    [Abstract] [Full Text] [Related]

  • 12. [Blood CA 19-9 in the diagnosis of carcinoma of the pancreas: a critical approach].
    Angonese C, Basso D, Del Favero G, Fabris C, Tremolada C, Plebani M, Burlina A, Naccarato R.
    Ann Ital Med Int; 1987 Apr; 2(2):138-42. PubMed ID: 3275279
    [No Abstract] [Full Text] [Related]

  • 13. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
    Jurkowska G, Kulpa J, Skrodzka D, Rogowski F.
    Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
    [Abstract] [Full Text] [Related]

  • 14. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study.
    Adamek HE, Albert J, Breer H, Weitz M, Schilling D, Riemann JF.
    Lancet; 2000 Jul 15; 356(9225):190-3. PubMed ID: 10963196
    [Abstract] [Full Text] [Related]

  • 15. [Autoimmune pancreatitis in a patient with ulcerative colitis simulating a pancreatic tumor].
    Bor R, Farkas K, Bálint A, Wittmann T, Nagy F, Tiszlavicz L, Molnár T, Szepes Z.
    Orv Hetil; 2014 Jun 22; 155(25):1000-4. PubMed ID: 24936576
    [Abstract] [Full Text] [Related]

  • 16. [The use of the carbohydrate antigen CA-19-9, the carcinoembryonic antigen and alpha fetoprotein in the diagnosis of pancreatic cancer].
    Skvortsov SV, Kalinin AV, Lytsar' BN.
    Vestn Ross Akad Med Nauk; 1993 Jun 22; (4):47-9. PubMed ID: 7687486
    [Abstract] [Full Text] [Related]

  • 17. The reliability of highly elevated CA 19-9 levels.
    Osswald BR, Klee FE, Wysocki S.
    Dis Markers; 1993 Dec 22; 11(5-6):275-8. PubMed ID: 8082316
    [Abstract] [Full Text] [Related]

  • 18. The influence of cholestasis on CA 50 and CA 242 in pancreatic cancer and benign biliopancreatic diseases.
    Pålsson B, Masson P, Andrén-Sandberg A.
    Scand J Gastroenterol; 1993 Nov 22; 28(11):981-7. PubMed ID: 8284635
    [Abstract] [Full Text] [Related]

  • 19. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein?
    Meggiato T, Basso D, Fabris C, Fogar P, Panozzo MP, Plebani M, Faggian D, Scalon P, Ferrara C, Del Favero G.
    Dis Markers; 1990 Nov 22; 8(4):171-7. PubMed ID: 1708317
    [Abstract] [Full Text] [Related]

  • 20. Novel tumour markers: a diagnostic role in pancreatic cancer?
    Roulston JE.
    Br J Cancer; 1994 Sep 22; 70(3):389-90. PubMed ID: 8080718
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.